Allozymes is applying innovative ultrahigh-throughput microfluidics technology to accelerate enzyme evolution and development. The company’s first target application is to transform ingredients manufacturing for industries ranging from pharmaceuticals and cosmetics to food and beverages.
Allozymes says it is capable achieving 10X faster and cheaper enzyme development with 200X higher chance of success and 1,000,000X less reagent consumption.
Founded in 2020 in Singapore, Allozymes is a graduate of the Entrepreneur First program which brings together talented founders and supports them at the earliest stages of company formation. The company’s Co-Founder and CTO Akbar Vahidi invented allozymes’ technology when he was serving as a lead research fellow at the National University of Singapore (NUS). Co-Founder and CEO Peyman Salehian also has a PhD from NUS, as well as extensive experience in transferring technologies from lab to the market.
Subscribe for alerts on new companies featured on Startups.Bio
Archon Biosciences is a biotech company pioneering computationally designed 'Antibody Cages' to unlock powerful therapeutic targets beyond the reach of existing modalities. Archon directly applies …
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company's multispecific antibodies are designed to harness …
The biotechnology sector is advancing rapidly, fueled by significant venture capital investments that are enabling companies to achieve major breakthroughs. To stay informed about the …
Founded in 2024, Analona Therapeutics is a biotech company located in Denmark focused on developing innovative antibody-based therapies for pancreatic cancer. The company is built …
